Last reviewed · How we verify
M.V.I. Pediatric (VITAMIN E)
M.V.I. Pediatric (Vitamin E) is a small molecule drug developed by HOSPIRA, currently owned by the same company. It targets glutathione S-transferase P and belongs to the vitamin E class. Originally approved by the FDA in 1953, it is indicated for the treatment of vitamin E deficiency. As a patented product, its commercial status is proprietary. Key safety considerations include potential interactions with other medications.
At a glance
| Generic name | VITAMIN E |
|---|---|
| Sponsor | Pfizer |
| Drug class | Vitamin E |
| Target | Glutathione S-transferase P |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
| First approval | 1953 |
Approved indications
- Vitamin E deficiency
Common side effects
Drug interactions
- warfarin
Key clinical trials
- A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy (PHASE2,PHASE3)
- Vitamin E Dosing Study (PHASE2)
- Vitamin E Pharmacokinetics and Biomarkers in Normal and Obese Women (PHASE1)
- Effect of Cream Paste Containg Pleuran on Selected Skin Dermatoses (Neonatal Pustulosis, Diaper Dermatitis, Perioral Dermatitis). (NA)
- Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia (PHASE2)
- Combination Gerotherapeutic Interventions for Healthspan Improvement (PHASE3)
- Examining the Impact of Exercise Training on Vascular Dysfunction in Individuals With Mental Health Disorders - Study 1 (NA)
- The Efficacy of Tocotrienol Rich Fraction for Liver Protection in Adult Patients With Alcoholic Fatty Liver Disease (AFLD) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- M.V.I. Pediatric CI brief — competitive landscape report
- M.V.I. Pediatric updates RSS · CI watch RSS
- Pfizer portfolio CI